Differences in immune cells engaged in cell-mediated immunity after chemotherapy for far advanced pancreatic cancer

Pancreas

Volumn 32, Issue 1, 2006, Pages 29-36

  Bang, Seungmin ^a   Kim, Han Soo ^b   Yee, Shin Choo ^b   Seung, Woo Park ^a,b   Jae, Bock Chung ^a   Si, Young Song ^a,b  

^a Division of Gastroenterology   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Cell mediated immunity; Chemotherapy; Dendritic cell; Immunotherapy; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CISPLATIN; GEMCITABINE; INTERLEUKIN 10; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELLULAR IMMUNITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; MALE; NATURAL KILLER T CELL; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 29144440850     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpa.0000191651.32420.41     Document Type: Article

References (39)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
2. Hiraoka T. Extended radical resection of cancer of the pancreas with intraoperative radiotherapy. Baillieres Clin Gastroenterol. 1990;4:985-993.
3. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993;165:68-72.
4. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.
5. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999;189:1-7.
6. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas - 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567-579.
7. Colaco C. Why are dendritic cells central to cancer immunology? Mol Med Today. 1999;5:14-17.
8. Lanzavecchia A. Identifying strategies for immune intervention. Science. 1993;260:937-944.
9. Pardoll DM. Cancer vaccines. Nat Med. 1998;4:525-531.
10. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Immunol Nat. 2001;2:293-299.
11. Hart I, Colaco C. Fusion induces tumor rejection. Nature. 1997;388:627-628.
12. Young JW, Inaba K. Dendritic cells as adjunvant for class I major histocompatability complex-restricted anti-tumor immunity. J Exp Med. 1996;183:7-11.
13. Banchereau J, Steinman RM. Dendritic cell and the control of immunity. Nature. 1998;392:245-252.
14. Ichihara F, Kono K, Takahashi A, et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 2003;9:4404-4408.
15. Kono K, Takahashi A, Ichihara F, et al. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res. 2002;8:1767-1777.
16. Rosenberg SA. A new era for cancer immunology based on the genes that encode cancer antigens. Immunity. 1999;10:281-287.
17. Lohr M, Hoffmeyer A, Kroger J, et al. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet. 2001;357:1591-1592.
18. Mitchell MS. Combination of anticancer drugs and immunotherapy. Cancer Immunol Immunother. 2003;52:686-692.
19. Nikitina EY, Gabrilovich DI. Combination of γ-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int J Cancer. 2001;94:825-833.
20. Rosenberg SA, Yang JC, Robbins PF, et al. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunol. 2003;63:385-393.
21. Takahashi T, Omuro Y, Matsumoto G, et al. Nonmyeloablative allogeneic stem cell transplantation for patients with unresectable pancreatic cancer. Pancreas. 2004;28:e65-e69.
22. Decker T, Lohmann-Matthes ML. quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods. 1988;115:61-69.
23. Ceuppens JL, Baroja ML, Katrien L, et al. Human T cell activation with phytohemagglutinin: the function of IL-6 as an accessory signal. J Immunol. 1988;141:3868-3874.
24. Alexander JP, Kudoh S, Melsop KA, et al. T cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res. 1993;53:1380-1387.
25. Kiessling R, Wasserman K, Horiguchi S, et al. Tumor-induced immune dysfunction. Cancer Immunol Immunother. 1999;48:353-362.
26. Young RC, Corder MP, Haynes HA, et al. Delayed hypersensitivity in Hodgkin's disease. A study of 103 untreated patients. Am J Med. 1972;52:63-68.
27. Marincola FM, Jaffee EM, Hicklin DJ, et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol. 2000;74:181-273.
28. Kiertscher SM, Luo J, Dubinett SM, et al. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol. 2000;164:1269-1279.
29. Rad AN, Pollara G, Sohaib SM, et al. The differential influence of allogenic tumor cell death via DNA damage on dendritic cell maturation and antigen presentation. Cancer Res. 2003;63:5143-5150.
30. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res. 1990;50:4417-4422.
31. Huang P, Chubb S, Hertel LW, et al. Action of 2′,2′- difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991;51:6110-6117.
32. Bergman AM, Ruiz van Haperen VW, Veerman G, et al. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res. 1996;2:521-530.
33. van Moorsel CJ, Pinedo HM, Veerman G, et al. Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur J Cancer. 1999;35:808-814.
34. Markowicz S, Walewski J, Zajda K, et al. Recovery of dendritic cell counts and function in peripheral blood of cancer patients after chemotherapy. Cytokines Cell Mol Ther. 2002;7:15-24.
35. Fortis C, Foppoli M, Gianotti L, et al. Increased interleukin-10 serum levels in patients with solid tumors. Cancer Lett. 1996;104:1-5.
36. Sulitzeanu D. Immunosuppressive factors in human cancer. Adv Cancer Res. 1993;60:247-267.
37. Teraoka H, Sawada T, Nishihara T, et al. Enhanced VEGF production and decreased immunogenicity induced by TGF-β1 promote liver metastasis of pancreatic cancer. Cancer Res. 2001;85:612-617.
38. Bellone G, Turletti A, Artusio E, et al. Tumor-associated transforming growth factor-β and interleukin-10 contribute to a system of Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol. 1999;155:537-547.
39. Karayiannakis AJ, Bolanaki H, Syrigos KN, et al. Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett. 2003;194:119-124.